Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect.
Severe haemophilia is a serious, haemorrhagic disorder of the plasmatic coagulation system. In this study we investigated, whether 'compensatory' activation of the platelet coagulation system occurs in this situation. Platelet function was investigated with aggregation, adhesion and flow cytometric assays. In addition, we performed clot and platelet plug formation tests and determined endogenous thrombin potentials in patients with severe haemophilia A or B; results were compared to those of healthy controls. Platelet aggregation in response to stimulation with ADP, ristocetin and epinephrine was similar in patients and controls; aggregation in response to collagen was reduced significantly in haemophiliacs. Flow cytometric analysis of P-selectin (CD 62P) and CD 63, of the conformationally changed GP IIb/IIIa with PAC 1 and of thrombospondin bound to CD 36 (GP IV) was performed at baseline and post stimulation. Baseline expression of all markers was similar in haemophiliacs and controls. After stimulation of the platelet thrombin receptors with the thrombin receptor activating peptide (TRAP) 6, the surface expression of all markers increased significantly; again, the expression was similar in haemophiliacs and controls. With thrombelastography and PFA 100 analysis, clot formation under low shear and platelet plug formation under high shear is measured. Both test results revealed a significantly reduced clot and platelet plug formation capacity in severe haemophiliacs. Our results did not reveal signs of enhanced platelet preactivation in haemophiliacs, indicating that baseline platelet reactivity in severe haemophilia remains in a neutral state, despite the severely haemorrhagic condition. As expected, both thrombin and clot formation capacities were impaired significantly in severe haemophilia. The reduced response to collagen-based platelet stimulation tests is indicative of a concomitant platelet function defect. This defect probably contributes to the intensity of bleeding events in patients with severe haemophilia.
Grünewald
M
M
Department of Haematology, Haemostaseology Division, University of Ulm, Ulm, Germany. martin.grunewald@medezin.uni-ulm.de
Siegemund
A
A
Grünewald
A
A
Konegen
A
A
Koksch
M
M
Griesshammer
M
M
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000368:Aged; D001777:Blood Coagulation; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D002648:Child; D003094:Collagen / Q000097:blood*; D004837:Epinephrine / Q000494:pharmacology; D005164:Factor IX / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005434:Flow Cytometry; D006467:Hemophilia A / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology*; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000502:physiology; D012016:Reference Values; D012310:Ristocetin / Q000494:pharmacology; D013917:Thrombin / Q000378:metabolism
D012310:Ristocetin; D000244:Adenosine Diphosphate; D005169:Factor VIII; D005164:Factor IX; D003094:Collagen; D013917:Thrombin; D004837:Epinephrine